Team
Science
Kumiko Ui-Tei, Ph.D. Co-Founder
Scientific Advisor・Chief Technology Officer
Director, NucleoTIDE and PepTIDE Drug Discovery Center, Institute of Science Tokyo
Project Professor, NucleoTIDE and PepTIDE Drug Discovery Center, Institute of Science Tokyo
Project Researcher, Graduate School of Science, The University of Tokyo
Adjunct Lecturer, Graduate School of Frontier Sciences, The University of Tokyo
Visiting Professor, Tokyo University of Science
The Inventor of SNPD-siRNA which is the key technology of ANRis Inc., and a pioneer in basic RNA science study.
After getting her Ph.D. from Graduate School of Science and Engineering at Waseda University, she started her career as a project researcher at Mitsubishi Kasei Institute of Life Sciences. Before assuming her current position, she was an assistant, a lecturer and an assistant professor at Nippon Medical School, and an associate professor at the Department of Biological Sciences, Graduate School of Science, The University of Tokyo.
The Society Award from Nucleic Acids Therapeutics Society of Japan (2019).
Takeshi Wada, Ph.D. Co-Founder
Scientific Advisor
Professor of Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science
Project Professor, NucleoTIDE and PepTIDE Drug Discovery Center, Institute of Science Tokyo
A specialist in the development of ligand-based DDS, the delivery system of nucleic acid drugs to the tissues in the body.
He got his Ph.D. from the Interdisciplinary Graduate School of Science and Engineering Tokyo Institute of Technology. He was an associate professor at The University of Tokyo before assuming his current position.
Co-Founder and Science Advisor of Wave Life Science, Inc.
The Society Award from Nucleic Acids Therapeutics Society of Japan (2018)
Hiroaki Taniguchi, MD, Ph.D. Co-Founder
Scientific Advisor
Professor, Division of Innovative Cancer Control Research, Cancer Research Institute of Kanazawa University
Experience in conducting the first trials of siRNA for both non-clinical and clinical in Japan.
Experience in conducting the first trials of siRNA for both non-clinical and clinical in Japan.
After getting his Ph.D. from Graduate School of Medicine, Sapporo Medical University, he started his career at the National Cancer Research Center in Spain. Before assuming his current position, he was a project assistant professor at Sapporo Medical University and a project associate professor at The Institute of Medical Science, The University of Tokyo. The Mizushima Award from The Japan Society of Drug Delivery System (2021)
Yoshimasa Asano, Ph.D.
Scientific Advisor
Assistant Professor, Laboratory of Health Science, School of Pharmacy, Nihon University
Contributed to the invention and validation of SNPD-siRNA which is the key technology of ANRis Inc., majoring in animal physiology.
After getting his Ph.D. from The University of Tokyo, he started his career as an assistant professor at the Department of Biological Sciences, Graduate School of Science, The University of Tokyo before assuming his current position.
Management
Wataru Kawamura, Ph.D.
CEO
Dr. Wataru Kawamura received his Ph.D. in Engineering from the University of Tokyo. He worked on drug delivery system (DDS) development and nucleic acid therapeutics at Teijin Limited and Nitto Denko Corporation, where he was involved in evaluating and advancing novel drug discovery and development programs. He has served as Representative Director and CEO of ANRis Inc. since February 2026
Kazuhiko Yamada, Ph.D.
Board Member
Completed the doctoral program at the Graduate School of Tokyo Medical and Dental University (currently Institute of Science Tokyo) and holds a Ph.D. in Science. At Eisai Co., Ltd., engaged in drug discovery research in the oncology field as well as biomarker and translational research, contributing to the clinical development of small-molecule drugs. Joined ANRis Inc. in October 2025 and has served as a Board Member since February 2026.
Daisuke Niwa
Board Member
Ted Yamamoto
Board Member
English 
日本語